Tag: IBI-376

Innovent Biologics begins parsaclisib phase 2 trial in follicular lymphoma

pharmanewsdaily- April 28, 2020

Innovent Biologics has dosed the first patient in a phase 2 trial of parsaclisib (IBI-376), a novel and selective PI3Kδ inhibitor in follicular lymphoma (FL). ... Read More